The Role Of Glycans In Arboviral Disease; From Immunomodulation To Glycotherapeutic Treatment Strategies
Funder
National Health and Medical Research Council
Funding Amount
$419,180.00
Summary
Dengue and chikungunya viruses are leading causes of emerging mosquito-transmitted (arboviral) disease worldwide. Currently there are no available vaccines or therapeutics making combatting these arboviral diseases one of our most pressing global health challenges. Preliminary evidence shows that glycan recognition is critical for disease immunopathogenesis. This project focuses on the role of viral glycans in arboviral disease with the aim of identifying and expanding on new therapeutic targets
Hepatitis C virus (HCV) and Human immunodeficiency virus (HIV) infect 200 million and 50 million people world-wide, respectively, and there are no preventative vaccines. The work outlined in this fellowship seeks to understand the structure and function of the major surface proteins of these viruses, their ability to be recognised by the immune system and to develop a novel vaccine for the prevention of HCV.
Herpesviruses infect most Australians and cause recurrent ulcers, birth defects and cancer. Infection lasts lifelong, and spreads to close contacts without obvious clinical signs. Thus disease is hard to prevent. However we can learn much from related animal infections. We have shown that both mouse and human herpesviruses enter mice via cells in the nose. Thus human infections might follow the same route. We will define what body defences work here and whether vaccines can prevent infection.
Understanding HIV Resistance To Entry Inhibitors To Advance The Development Of Novel Antivirals
Funder
National Health and Medical Research Council
Funding Amount
$877,585.00
Summary
We cannot afford to be complacent in the search for improved anti HIV drugs for 2 principal reasons; First, worldwide a staggering 66% of infected individuals who need treatment are still unable to access therapy; and Second, the main reason why most treated patients are now living longer and more healthy lives is because we have never stopped developing newer therapies to provide options for patients. In this study we will develop and test newer drugs that block HIV infection of cells.
Hepatitis C Virus infects 3% of the world's population causing recurring liver disease, cirrhosis and hepatocellular carcinoma. To infect a liver cell, the viral glycoproteins attach to cell surface molecules wher they are activated to mediate merger of the viral and cellular membranes. This project grant will explore how the viral glycopropteins become activated and obtain essential structural information on the viral glycoproteins. These studies will help us to design antiviral agents.
Roles Of The Hepatitis C Virus Glycoprotein E2 Variable Regions In Virus Entry, Immunogenicity And Immune Evasion.
Funder
National Health and Medical Research Council
Funding Amount
$682,820.00
Summary
Hepatitis C Virus infects 200 million people world-wide with over 200,000 Australians infected with the disease. This project will examine how the surface proteins of HCV change their shape to evade antibody responses and how this effects the outcome of infection. We will further characterize a vaccine that elicits protective immunity to HCV to identify the optimal formulation for clinical trials.
Elucidating The Activation Mechanism Of The HIV-1 Envelope Glycoproteins, Gp120-gp41
Funder
National Health and Medical Research Council
Funding Amount
$636,973.00
Summary
Antiretrovirals prolong the life of HIV+ people, however toxicity and resistance issues persist. We aim to understand how the HIV surface proteins effect viral entry in order to identify new antiviral targets.
Influenza remains an important disease and exacts a high toll in both morbidity and mortality each year. This project will identify the carbohydrates that are utilised by influenza virus to initiate infection throughout the body and map how these carbohydrates interact with the key viral surface proteins. This research will provide new insight into the emergence of new influenza virus strains and cross-species pathogenicity.